Risk factors for treatment failure in scabies: a cohort study.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
04 2019
Historique:
accepted: 21 10 2018
pubmed: 31 10 2018
medline: 6 5 2020
entrez: 31 10 2018
Statut: ppublish

Résumé

Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. To identify predictors of treatment failure of scabies in ambulatory populations. This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7). Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.

Sections du résumé

BACKGROUND
Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries.
OBJECTIVES
To identify predictors of treatment failure of scabies in ambulatory populations.
METHODS
This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment.
RESULTS
In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7).
CONCLUSIONS
Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.

Identifiants

pubmed: 30376179
doi: 10.1111/bjd.17348
doi:

Substances chimiques

Antiparasitic Agents 0
Benzoates 0
Ivermectin 70288-86-7
benzyl benzoate N863NB338G

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

888-893

Investigateurs

S Bechu (S)
N Mion-Mouton (N)
O Lafaurie (O)
A Barrel (A)
M Pulluard (M)
V Hamel (V)
M X Dore (MX)
E Duflo (E)
S Lardans-Cassius (S)
J C Rzeznik (JC)
S Baricault (S)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 British Association of Dermatologists.

Auteurs

A Aussy (A)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

E Houivet (E)

Department of Biostatistics, Rouen University Hospital and INSERM U1219, University of Rouen Normandie, Rouen, France.

V Hébert (V)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

H Colas-Cailleux (H)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

N Laaengh (N)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

C Richard (C)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

M Ouvry (M)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

C Boulard (C)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

S Léger (S)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

N Litrowski (N)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

J Benichou (J)

Department of Biostatistics, Rouen University Hospital and INSERM U1219, University of Rouen Normandie, Rouen, France.

P Joly (P)

Department of Dermatology, Rouen University Hospital and INSERM U1234, University of Rouen Normandie, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH